Инволютивные изменения вульвовагинальной области

Обложка


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Инволютивные изменения вульвовагинальной области подразумевают ряд трансформаций, приводящих к вульвовагинальной атрофии в период менопаузы. Признаки и симптомы, наиболее часто отмечаемые при данном синдроме, — сухость влагалища (54,4–100%), диспареуния (17,6–77,6%), жжение (2,0–56,9%), зуд (7,8–56,6%) и дизурия (5,9–36,1%). Другие жалобы включают деформацию вульвы, раздражение, а также рецидивирующие бактериальные инфекции мочевыводящих путей или влагалища, дрожжевую инфекцию. Сухость, диспареуния и раздражение влагалища — это симптомы, которые больше всего влияют на качество жизни женщины.

В статье проанализированы современные представления о мочеполовом синдроме менопаузы, изучены механизмы его возникновения, описана клиническая картина. Подробно рассматриваются вопросы терапии атрофии вульвовагинальной области, особое внимание уделено физиотерапевтическим методам лечения.

Полный текст

Доступ закрыт

Об авторах

Сергей Иванович Суркичин

Центральная государственная медицинская академия Управления делами Президента Российской Федерации

Автор, ответственный за переписку.
Email: surkichinsi24@mail.ru
ORCID iD: 0000-0003-0521-0333

к.м.н., доцент

Россия, Москва

Лариса Сергеевна Круглова

Центральная государственная медицинская академия Управления делами Президента Российской Федерации

Email: surkichinsi24@mail.ru
ORCID iD: 0000-0002-5044-5265
SPIN-код: 1107-4372

д.м.н.

Россия, Москва

Инна Анатольевна Аполихина

Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени В.И. Кулакова

Email: surkichinsi24@mail.ru
ORCID iD: 0000-0002-4581-6295
SPIN-код: 6282-7435

д.м.н., профессор

Россия, Москва

Роман Юрьевич Майоров

Центральная государственная медицинская академия Управления делами Президента Российской Федерации

Email: surkichinsi24@mail.ru
ORCID iD: 0000-0003-1911-6743
Россия, Москва

Марика Авин

Медицинский центр «Столица»

Email: surkichinsi24@mail.ru
ORCID iD: 0000-0002-8317-0800
Россия, Москва

Список литературы

  1. Portman D.J., Gass M.L., on behalf of the Vulvovaginal Atrophy Conference Panel: Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society // Climateric. 2014. Vol. 21. Р. 1063–1068. doi: 10.1097/GME.0000000000000329
  2. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society // Menopause. 2013. Vol. 20, N 9. Р. 888–902;quiz 903-4. doi: 10.1097/GME.0b013e3182a122c2
  3. Robinson D., Cardozo L. The pathophysiology and management of postmenopausal urogenital oestrogen deficiency // J Br Menopause Soc. 2001. Vol. 7, N 2. Р. 67–73. doi: 10.1258/136218001100321263
  4. Ettinger B., Hait H., Reape K.Z., Shu H. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach // Menopause. 2008. Vol. 15, N 5. Р. 885–889. doi: 10.1097/gme.0b013e318182f84b
  5. Palacios S., Nappi R.E., Bruyniks N., et al. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause // Climacteric. 2018. Vol. 21, N 3. Р. 286–291. doi: 10.1080/13697137.2018.1446930
  6. Nappi R.E., Seracchioli R., Salvatore S., et al. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study // Gynecol Endocrinol. 2019. Vol. 35, N 5. Р. 453–459. doi: 10.1080/09513590.2018.1563883
  7. Lester J., Pahouja G., Andersen B., Lustberg M. Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue // J Pers Med. 2015. Vol. 5, N 2. Р. 50–66. doi: 10.3390/jpm5020050
  8. Palma F., Xholli A., Cagnacci A., as the writing group of the AGATA study. The most bothersome symptom of vaginal atrophy: Evidence from the observational AGATA study // Maturitas. 2018. Vol. 108. Р. 18–23. doi: 10.1016/j.maturitas.2017.11.007
  9. Nappi R.E., Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) ― results from an international survey // Climacteric. 2012. Vol. 15, N 1. Р. 36–44. doi: 10.3109/13697137.2011.647840
  10. Omi T., Numano K. The role of the CO2 laser and fractional CO2 laser in dermatology // Laser Ther. 2014. Vol. 23, N 1. Р. 49–60. doi: 10.5978/islsm.14-RE-01
  11. Andelloux M. Products for sexual lubrication: understanding and addressing options with your patients // Nurs Womens Health. 2011. Vol. 15, N 3. Р. 253–257. doi: 10.1111/j.1751-486X.2011.01642.x
  12. Kennedy S.H., Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants // J Clin Psychopharmacol. 2009. Vol. 29, N 2. Р. 157–164. doi: 10.1097/JCP.0b013e31819c76e9
  13. Edwards D., Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? // Climacteric. 2016. Vol. 19, N 2. Р. 151–161. doi: 10.3109/13697137.2015.1124259
  14. Nappi R.E., Palacios S., Bruyniks N., et al.; investigators ES. The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey // Menopause. 2018. Vol. 26, N 5. Р. 485–491. doi: 10.1097/GME.0000000000001260
  15. Kingsberg S.A., Larkin L., Krychman M., et al. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history // Menopause. 2019. Vol. 26, N 2. Р. 124–131. doi: 10.1097/GME.0000000000001194
  16. De Landsheere L., Munaut C., Nusgens B., et al. Histology of the vaginal wall in women with pelvic organ prolapse: a literature review // Int Urogynecol J. 2013. Vol. 24, N 12. Р. 2011–2020. doi: 10.1007/s00192-013-2111-1
  17. Gandhi J., Chen A., Dagur G., et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management // Am J Obstet Gynecol. 2016. Vol. 215, N 6. Р. 704–711. doi: 10.1016/j.ajog.2016.07.045
  18. Phillips N.A., Bachmann G.A. Genitourinary syndrome of menopause: common problem, effective treatments // Cleve Clin J Med. 2018. Vol. 85, N 5. Р. 390–398. doi: 10.3949/ccjm.85a.15081
  19. Lachowsky M., Nappi R.E. The effects of oestrogen on urogenital health // Maturitas. 2009. Vol. 63, N 2. Р. 149–151. doi: 10.1016/j.maturitas.2009.03.012
  20. Briggs P. Genitourinary syndrome of menopause // Post Reprod Health. 2020. Vol. 26, N 2. Р. 111–114. doi: 10.1177/2053369119884144
  21. Athanasiou S., Pitsouni E., Antonopoulou S., et al. The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women // Climacteric. 2016. Vol. 19, N 5. Р. 512–518. doi: 10.1080/13697137.2016.1212006
  22. Mac Bride M.B., Rhodes D.J., Shuster L.T. Vulvovaginal atrophy // Mayo Clin Proc. 2010. Vol. 85, N 1. Р. 87–94. doi: 10.4065/mcp.2009.0413
  23. Am F.E. Genitourinary syndrome of menopause // Aust Fam Physician. 2017. Vol. 46, N 7. Р. 481–484.
  24. Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women // J Womens Health (Larchmt). 2010. Vol. 19, N 3. Р. 425–432. doi: 10.1089/jwh.2009.1384
  25. Jannini E.A., Nappi R.E. Couplepause: a new paradigm in treating sexual dysfunction during menopause and andropause // Sex Med Rev. 2018. Vol. 6, N 3. Р. 384–395. doi: 10.1016/j.sxmr.2017.11.002
  26. Bachmann G. Urogenital ageing: an old problem newly recognized // Maturitas. 1995. Vol. 22. Р. S1–S5. doi: 10.1016/0378-5122(95)00956-6
  27. Palacios S., Mejía A., Neyro J.L. Treatment of the genitourinary syndrome of menopause // Climacteric. 2015. Vol. 18, Suppl. 1. Р. 23–29. doi: 10.3109/13697137.2015.1079100
  28. ACOG Committee No. Opinion 659. The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer // Obstet Gynecol. 2016. Vol. 127, N 3. Р. e93–96. doi: 10.1097/AOG.0000000000001351
  29. Bachmann G.A., Komi J.O. Ospemifene effectively treats vulvovaginal atrophyin postmenopausal women: results from a pivotal phase 3 study // Menopause. 2010. Vol. 17, N 3. Р. 480–486. doi: 10.1097/gme.0b013e3181c1ac01
  30. Portman D.J., Bachmann G.A., Simon J.A. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy // Menopause. 2013. Vol. 20, N 6. Р. 623–630. doi: 10.1097/gme.0b013e318279ba64
  31. Ampt A.J., Roach V., Roberts C.L. Vulvoplasty in New South Wales, 2001–2013: a population-based record linkage study // Med J Aust. 2016. Vol. 205, N 8. Р. 365–369. doi: 10.5694/mja16.00512
  32. Barbara G., Facchin F., Buggio L., et al. Vaginal rejuvenation: current perspectives // Int J Womens Health. 2017. Vol. 9. Р. 513–519. doi: 10.2147/IJWH.S99700
  33. Kaplan I. The CO2 surgical laser // Photomed Laser Surg. 2010. Vol. 28. Р. 847–848.
  34. Gold M., Andriessen A., Bader A., et al. Review and clinical experience exploring evidence, clinical efficacy, and safety regarding nonsurgical treatment of feminine rejuvenation // J Cosmet Dermatol. 2018. Vol. 17, N 3. Р. 289–297. doi: 10.1111/jocd.12524
  35. Salvatore S., Athanasiou S., Candiani M. The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy // Curr Opin Obstet Gynecol. 2015. Vol. 27. Р. 504–508. doi: 10.1097/GCO.0000000000000230
  36. Salvatore S., Nappi R.E., Zerbinati N., et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study // Climacteric. 2014. Vol. 17, N 4. Р. 363–369. doi: 10.3109/13697137.2014.899347
  37. Samuels J.B., Garcia M.A. Treatment to external labia and vaginal canal with CO2 laser for symptoms of vulvovaginal atrophy in postmenopausal women // Aesthet Surg J. 2019. Vol. 39, N 1. Р. 83–93. doi: 10.1093/asj/sjy087
  38. Quick A.M., Zvinovski F., Hudson C., et al. Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors // Support Care Cancer. 2020. Vol. 28, N 8. Р. 3669–3677. doi: 10.1007/s00520-019-05211-3
  39. Sokol E.R., Karram M.M. An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy // Menopause. 2016. Vol. 23, N 10. Р. 1102–1107. doi: 10.1097/GME.0000000000000700
  40. Pitsouni E., Grigoriadis T., Tsiveleka A., et al. Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: an observational study // Maturitas. 2016. Vol. 94. Р. 131–136. doi: 10.1016/j.maturitas.2016.09.012
  41. Arroyo C. Fractional CO2 laser treatment for vulvovaginal atrophy symptoms and vaginal rejuvenation in perimenopausal women // Int J Women Health. 2017. Vol. 9. Р. 591–595. doi: 10.2147/IJWH.S136857
  42. Athanasiou S., Pitsouni E., Falagas M.E., et al. CO2 laser for the genitourinary syndrome of menopause. How many laser sessions? // Maturitas. 2017. Vol. 104. Р. 24–28. doi: 10.1016/j.maturitas.2017.07.007
  43. Eder S.E. Early effect of fractional CO2 laser treatment in post-menopausal women with vaginal atrophy // Laser Ther. 2018. Vol. 27, N 1. Р. 41–47. doi: 10.5978/islsm.18-OR-04
  44. Tovar-Huamani J., Mercado-Olivares F., Grandez-Urbina J.A., et al. Efficacy of fractional CO2 laser in the treatment of genitourinary syndrome of menopause in Latin-American Population: First Peruvian experience // Lasers Surg Med. 2019. Vol. 51, N 6. Р. 509–515. doi: 10.1002/lsm.23066
  45. Siliquini G.P., Tuninetti V., Bounous V.E., et al. Fractional CO2 laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women // Climacteric. 2017. Vol. 20, N 4. Р. 379–384. doi: 10.1080/13697137.2017.1319815
  46. Becorpi A., Campisciano G., Zanotta N., et al. Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects // Lasers Med Sci. 2018. Vol. 33, N 5. Р. 1047–1054. doi: 10.1007/s10103-018-2471-3
  47. Perino A., Calligaro A., Forlani F., et al. Vulvovaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser // Maturitas. 2015. Vol. 80, N 3. Р. 296–301. doi: 10.1016/j.maturitas.2014.12.006
  48. Cruz V.L., Steiner M.L., Pompei L.M., et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women // Menopause. 2018. Vol. 25, N 1. Р. 21–28. doi: 10.1097/GME.0000000000000955
  49. Pieralli A., Fallani M.G., Becorpi A., et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors // Arch Gynecol Obstet. 2016. Vol. 294, N 4. Р. 841–846. doi: 10.1007/s00404-016-4118-6
  50. Behnia-Willison F., Sarraf S., Miller J., et al. Safety and long-term efficacy of fractional CO2 laser treatment in women suffering from genitourinary syndrome of menopause // Eur J Obstet Gynecol Reprod Biol. 2017. Vol. 213. Р. 39–44. doi: 10.1016/j.ejogrb.2017.03.036
  51. Salvatore S., Nappi R.E., Parma M., et al. Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy // Climacteric. 2015. Vol. 18, N 2. Р. 219–225. doi: 10.3109/13697137.2014.975197
  52. Maggiore L.U., Parma M., Candiani M., Salvatore S. Microablative fractional CO2 laser for vulvovaginal atrophy in women with a history of breast cancer // J Minim Invasive Gynecol. 2015. Vol. 22, N 6S. Р. S100. doi: 10.1016/j.jmig.2015.08.269
  53. Harris V., Dickison P., Lim A., Fischer G. Vulvo-vaginal rejuvenation: Fact or fiction? Fractional carbon dioxide laser for genitourinary syndrome of menopause // Australas J Dermatol. 2018. Vol. 59, N 4. Р. 341–343. doi: 10.1111/ajd.12765
  54. Pagano I., Gieri S., Nocera F., et al. Evaluation of the CO2 laser therapy on vulvo-vaginal atrophy (VVA) in oncological patients: preliminary results // J Can Ther. 2017. Vol. 8, N 5. Р. 452–463. doi: 10.4236/jct.2017.85039
  55. Samuels J.B., Garcia M.A. Treatment to external labia and vaginal canal with CO2 laser for symptoms of vulvovaginal atrophy in postmenopausal women // Aesthet. 2019. Vol. 39, N 1. Р. 83–93. doi: 10.1093/asj/sjy087
  56. Gordon C., Gonzales S., Krychman M.L. Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy // Menopause. 2019. Vol. 26, N 4. Р. 423–427. doi: 10.1097/GME.0000000000001293
  57. Athanasiou S., Pitsouni E., Grigoriadis T., et al. Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results // Menopause. 2019. Vol. 26, N 3. Р. 248–255. doi: 10.1097/GME.0000000000001206
  58. Sokol E.R., Karram M.M. Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes // Menopause. 2017. Vol. 24, N 7. Р. 810–814. doi: 10.1097/GME.0000000000000839
  59. Cruz V.M., Wajsfeld T., Steiner M.M., et al. Vaginal CO2 laser versus topical estriol treatment for vaginal atrophy in postmenopausal women: 1-year follow-up [20P] // Obstet Gynecol. 2019. Vol. 133, Suppl 1. Р. 175–176. doi: 10.1097/01.AOG.0000558908.60309.79
  60. Food and Drug Admnistration. FDA warns against use of energy-based devices to perform vaginal ‘rejuvenation’ or vaginal cosmetic procedures [accessed on 16 September 2019]. FDA Safety Communication; 2018. Available from: https://www.iuga.org/news/fda-warns-against-use-of-energy-based-devices-to-perform-vaginal-rejuvenation-or-vaginal-cosmetic-procedures-fda-safety-communication
  61. Gambacciani M., Levancini M., Russo E., et al. Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause // Climacteric. 2018. Vol. 21, N 2. Р. 148–152. doi: 10.1080/13697137.2018.1436538
  62. Gambacciani M., Levancini M., Cervigni M. Vaginal erbium laser: the second generation thermotherapy for the genitourinary syndrome of menopause // Climacteric. 2015. Vol. 18, N 5. Р. 757–763. doi: 10.3109/13697137.2015.1045485
  63. Gaspar A., Brandi H., Gomez V., Luque D. Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause // Lasers Surg Med. 2017. Vol. 49, N 2. Р. 160–168. doi: 10.1002/lsm.22569
  64. Bojanini J.F. Treatment of genitourinary syndrome of menopause with Erbium:YAG laser: a prospective study of efficacy and safety of the treatment for women after menopause of natural origin and therapy-induced menopause in breast cancer survivors // J Laser Health Academy. 2016. Vol. 2016, N 1. Р. 35–40.
  65. Gambacciani M., Levancini M. Short-term effect of vaginal erbium laser on the genitourinary syndrome of menopause // Minerva Ginecol. 2015. Vol. 67, N 2. Р. 97–102.
  66. Areas F., Valadares A.L., Conde D.M., Costa-Paiva L. The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitourinary syndrome of menopause: a prospective study // Menopause. 2019. Vol. 26, N 9. Р. 1052–1058. doi: 10.1097/GME.0000000000001353
  67. Gaviria J.E., Korosec B., Fernandez J., Montero G. Up to 3-year follow-up of patients with vaginal relaxation syndrome participating in laser vaginal tightening // J Laser Health Academy. 2016. Vol. 2016, N 1. Р. 6–11.
  68. Pagano T., De Rosa P., Vallone R., et al. Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study // Menopause. 2018. Vol. 25, N 6. Р. 657–662. doi: 10.1097/GME.0000000000001053
  69. Pagano T., De Rosa P., Vallone R., et al. Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study // Menopause. 2016. Vol. 23, N 10. Р. 1108–1113. doi: 10.1097/GME.0000000000000672
  70. Caruth J.C. Evaluation of the safety and efficacy of a novel radiofrequency device for vaginal treatment // Surg Technol Int. 2018. Vol. 32. Р. 145–149.
  71. Vicariotto F., Raichi M. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device // Minerva Ginecol. 2016. Vol. 68, N 3. Р. 225–236.
  72. Vicariotto F., de Seta F., Faoro V., Raichi M. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety // Minerva Ginecol. 2017. Vol. 69, N 4. Р. 342–349. doi: 10.23736/S0026-4784.17.04072-2
  73. Alinsod R.M. Transcutaneous temperature controlled radiofrequency for atrophic vaginitis and dyspareunia // J Minim Invasive Gynecol. 2015. Vol. 22, N 6S. Р. S226–S227. doi: 10.1016/j.jmig.2015.08.798
  74. ACOG Position Statement. Fractional laser treatment of vulvovaginal atrophy and U.S. Food and Drug Administration clearance [accessed on 16 September 2019]. The American College of Obstetricians and Gynecologists; Washington, DC, USA; 2016. Available from: https://www.menopause.org/docs/default-source/default-document-library/nams-responds-to-fda-mandate-on-vaginal-laser-manufacturers-08-01-2018.pdf
  75. Ruiz-Rodriguez R., Sanz-Sánchez T., Córdoba S. Photodynamic photorejuvenation // Dermatol Surg. 2002. Vol. 28, N 8. Р. 742–744. doi: 10.1046/j.1524-4725.2002.02018.x
  76. Kohl E., Torezan L.A., Landthaler M., et al. Aesthetic effects of topical photodynamic therapy // J Eur Acad Dermatol Venereol. 2010. Vol. 24, N 11. Р. 1261–1269. doi: 10.1111/j.1468-3083.2010.03625.x
  77. Philipp-Dormston W.G. Photodynamic therapy for aesthetic-cosmetic indications // G Ital Dermatol Venereol. 2018. Vol. 153, N 6. Р. 817–826. doi: 10.23736/S0392-0488.18.05982-5
  78. Morton C.A., Szeimies R.M., Basset-Séguin N., et al. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 2: emerging indications — field cancerization, photorejuvenation and inflammatory/infective dermatoses // J Eur Acad Dermatol Venereol. 2020. Vol. 34. Р. 17–29. doi: 10.1111/jdv.16044
  79. Marmur E.S., Phelps R., Goldberg D.J. Ultrastructural changes seen after ALA-IPL photorejuvenation: a pilot study // J Cosmet Laser Ther. 2005. Vol. 7, N 1. Р. 21–24. doi: 10.1080/147641700510037725
  80. Orringer J.S., Hammerberg C., Hamilton T., et al. Molecular effects of photodynamic therapy for photoaging // Arch Dermatol. 2008. Vol. 144, N 10. Р. 1296–1302. doi: 10.1001/archderm.144.10.1296
  81. Sakamoto F.H., Lopes J.D., Anderson R.R. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: Part I. Acne vulgaris: when and why consider photodynamic therapy? // J Am Acad Dermatol. 2010. Vol. 63, N 2. Р. 183–193. doi: 10.1016/j.jaad.2009.09.056
  82. Rossi R., Bruscino N., Ricceri F., et al. Photodynamic treatment for viral infections of the skin // G Ital Dermatol Venereol. 2009. Vol. 144, N 1. Р. 79–83.
  83. Zhang F., Li D., Shi L., et al. 5-ALA-photodynamic therapy in refractory vulvar lichen sclerosus et atrophicus // Int J Clin Exp Pathol. 2020. Vol. 13, N 12. Р. 3100–3110.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Эко-Вектор", 2021


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86508 от 11.12.2023. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80650 от 15.03.2021 г.


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах